P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA
Patrick K. Reville(The University of Texas MD Anderson Cancer Center), Michael R. Green(Harvard University), Ashley Wilson(Center for Infectious Disease Research), Jared Henderson(The University of Texas MD Anderson Cancer Center), Helgi van de Velde(Sanofi (Belgium)), Linghua Wang(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Qing Deng(Central South University), Kamlesh Bisht, Sydney Parsons(The University of Texas MD Anderson Cancer Center), Chizitara Okwuchi(The University of Texas MD Anderson Cancer Center), Peter Kim(Sanofi (United States)), C. Le(The University of Texas MD Anderson Cancer Center), Hongfang Wang(Memorial Sloan Kettering Cancer Center), Estela Rojas(The University of Texas MD Anderson Cancer Center), Enyu Dai(The University of Texas MD Anderson Cancer Center), Shyanne Ruby Lockman(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k